User:James Bahng/sandbox 1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
== Structure of Fumarylacetoacetate Hydrolase with Phosphorus-based Inhibitor ==
== Structure of Fumarylacetoacetate Hydrolase with Phosphorus-based Inhibitor ==
-
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
 
-
1HYO is an EC 3.7.1.2 hydrolase cleaving C-C bonds in ketone bodies.
+
<StructureSection load='1hyo' size='340' side='right' caption='Caption for this structure' scene=''>
-
<scene name='58/581360/Overview/1'>TextToBeDisplayed</scene>
+
-
This is a default text for your page '''James Bahng/sandbox 1'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
+
1HYO is an EC 3.7.1.2 hydrolase involved in the final step of the Phe/Tyr catabolic pathway, and <scene name='58/581360/Ligand_bound/1'>binds to Fumarylacetoacetate</scene> producing [[http://ec.asm.org/content/6/3/514/F1.large.jpg Fumarate and Acetoacetate]].
-
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.
+
-
== Function ==
+
The mechanism is not well understood, but is hypothesized that His-133 activates a nucleophilic water, which attacks the δ carbon, leading to cleavage. The resultant tetrahedral alkoxy transition state are stabilized by
Line 14: Line 11:
Mutations in 1HYO are responsible for hereditary tyrosemia Type I, a serious metabolic disease resulting in chronic inflammation of the liver and neuronal damage. It is in the same metabolic pathway as Phenylketonuria (PKU) in infants, and is treated similarly with strict dietary control and pharmacological inhibition of Phenylalanine hydroxylase, the key first enzyme in the degradation pathway.
Mutations in 1HYO are responsible for hereditary tyrosemia Type I, a serious metabolic disease resulting in chronic inflammation of the liver and neuronal damage. It is in the same metabolic pathway as Phenylketonuria (PKU) in infants, and is treated similarly with strict dietary control and pharmacological inhibition of Phenylalanine hydroxylase, the key first enzyme in the degradation pathway.
 +
In very serious acute cases, double liver/kidney transplant may be considered as an option as well.
== Relevance ==
== Relevance ==

Revision as of 04:14, 1 April 2014

Structure of Fumarylacetoacetate Hydrolase with Phosphorus-based Inhibitor

Caption for this structure

Drag the structure with the mouse to rotate

References

Proteopedia Page Contributors and Editors (what is this?)

James Bahng

Personal tools